Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride
monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the ...
Nilotinib may cause QT prolongation (an irregular heart rhythm that can lead to
fainting, loss of consciousness, seizures, or sudden death). Tell your doctor if you
This page contains brief information about nilotinib and a collection of links to
more information about the use of this drug, research results, and ongoing
Jul 3, 2013 ... Information from the FDA about the approval of nilotinib and the clinical trials that
led to the approval.
Jan 2, 2015 ... Read about the cancer treatment drug nilotinib, otherwise known as Tasigna,
including what it is, how it works and possible side effects.
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under
investigation as a possible treatment for chronic myelogenous leukemia (CML).
In June ...
Oct 21, 2015 ... The NPF Recommends Further Study but Not Clinical Use of this Investigational
Drug. Tasigna (Nilotinib) is a leukemia drug that has recently ...
(nye-LOE-ti-nib). Generic Name: nilotinib. Trade Name(s): Tasigna. Nilotinib is
the generic for the trade chemotherapy drug Tasigna. In some cases, health care
May 27, 2015 ... Information on the drug nilotinib (Tasigna) prescribed for the treatment of
leukemia. Side effects, drug interactions, dosing information, and ...
May 19, 2016 ... The bioavailability of nilotinib might be reduced in patients with total gastrectomy
(see section 5.2). More frequent follow-up of these patients ...